GeoVax Advances COVID-19, Oncology, and Biosecurity Vaccine Programs Despite BARDA Award Termination
TL;DR
GEO-CM04S1 vaccine shows promise as booster to mRNA vaccines, targeting immunocompromised individuals, offering competitive edge in COVID-19 protection market.
GEO-CM04S1 utilizes synthetic-MVA platform expressing S and N antigens, offering broader, more durable protection through multi-antigen approach.
GeoVax's vaccines and immunotherapies address critical unmet needs in oncology, infectious diseases, and biodefense, aiming to make the world healthier and safer.
Published peer-reviewed article highlights GeoVax's innovative approach to COVID-19 vaccines, paving the way for broader immune responses and future advancements.
Found this article helpful?
Share it with your network and spread the knowledge!
GeoVax Labs, a clinical-stage biotechnology company, is advancing multiple vaccine and immunotherapy programs across infectious diseases and oncology, demonstrating resilience after the unexpected termination of its Project NextGen award by BARDA.
The company's COVID-19 vaccine candidate, GEO-CM04S1, remains a primary focus, with ongoing Phase 2 trials targeting immunocompromised populations. The multi-antigen vaccine, utilizing a synthetic-MVA platform, aims to provide broader and more durable protection compared to existing mRNA vaccines. Interim data from trials in chronic lymphocytic leukemia and stem cell transplant patients show promising results.
In oncology, GeoVax is preparing to initiate a Phase 2 trial for Gedeptin®, a gene-directed therapy for recurrent head and neck cancer. The treatment, which has received Orphan Drug designation, represents a potential breakthrough for patients with limited treatment options.
The company is also developing GEO-MVA, a vaccine candidate targeting Mpox and smallpox. Planned clinical trials in the second half of 2025 position GeoVax to offer a U.S.-developed alternative to foreign-sourced vaccines amid rising global biosecurity concerns.
Financially, GeoVax reported a net loss of $5.4 million for the first quarter of 2025, slightly improved from $5.9 million in the same period of 2024. The company maintains a cash balance of $7.4 million and continues to invest in innovative vaccine manufacturing processes, including developing scalable, cost-effective production methods.
With estimated market potentials exceeding $30 billion for its COVID-19 vaccine, $15 billion for oncology treatments, and $10 billion for its Mpox/smallpox vaccine, GeoVax remains committed to addressing critical unmet medical needs across multiple therapeutic areas.
Curated from NewMediaWire
